hit tracker
prime news list

all information about tech and other

Coming soon: Insulin injections once a week?

Coming soon: Insulin injections once a week?

By Denise Mann
HealthDay Reporter

MONDAY, March 22, 2021 (HealthDay News) – Daily insulin owners may be the test of the existence of people with type 2 diabetes, but weekly insulin shots may be a change in research for these people.

While the research is in its infancy, a new drug called basal insulin Fc (BIF) is given once a week and seems to be just as effective at controlling blood sugar (glucose) as insulin degludec, the gold standard once-a-year. shot of the day.

Insulin taken once a week is as safe as degludec and may be better at reducing the risk of dangerous low blood sugar (hypoglycemia) day and night, new research has shown.

The main benefit of insulin once a week is that more people will be willing to complete the treatment, said Dr. John Buse, head of endocrinology and director of the Diabetes Center at the University of North Carolina at Chapel Hill. Improvements prevent the complications of diabetes, including heart disease, vision loss, and kidney problems.


“There are 52 injections a year, more than 365 and 700+,” said Buse, who was not involved in the new study. “On the 100th anniversary of the discovery of insulin, it is amazing to see constant innovation in insulin therapy.”

Insulin degludec and persistent BIF are basal or posterior forms of insulin. They control blood sugar levels between meals and are released 24 hours a day. Some types of basal insulin are given twice a day. In contrast, insulin bolus is given after meals and when blood sugar rises. Taking insulin once a week should not control your blood sugar level and prevent you from taking more insulin as needed.

The 32-week study included nearly 400 people with type 2 diabetes, a form of the disease that is closely linked to obesity. Participants were assigned to one of three treatment groups: weekly BIF injections in one of two doses, or once daily insulin degludec injections.

Blood sugar control was similar in the case of people who received a weekly shot and those who took daily shots measured by hemoglobin A1C. This provides a snapshot of blood sugar for the last two to three months.


In addition, weekly shots had significantly lower rates of hypoglycemia.

“Daily insulin concentrations are more stable with weekly shooting and this improvement can lead to less hypoglycemia,” explains study author Juan Pablo Frias, medical director of the Los Angeles National Research Institute.

It was a phase 2 study. This means that new medicines must be made in advance if they are to reach the path or reach consumers. But if things go as planned, it would be available by 2023, Frias said. Once a week insulin shots are being developed by Eli Lilly and Co, who funded the new research.

The findings were unveiled on Sunday at the annual meeting of the Endocrine Association. Findings presented at medical meetings are considered preliminary until they are published in a peer-reviewed journal.

Further research is needed to confirm these findings, but weekly plans may be important for people with diabetes who have difficulty managing medications, the elderly, those with memory difficulties, and those with physical disabilities who may have a way to make daily plans. , said Dr. Deena Adimoolam, a New York physician and spokeswoman for the Endocrine Association.


“Many patients with insulin-dependent type 2 diabetes have a complicated medication regimen on a daily basis to use insulin, other injectables, and oral medications,” said Adimoolam, who was not involved in the study. “Basal insulin available as an injection once a week would be a much easier option for patients than remembering to take basal insulin every day.”

Buse was accepted. “It is gratifying to hear that so many more people are taking advantage of this product that loads less insulin to maintain good health,” he said.

More information

To learn more about diabetes and its treatments, visit Endocrine Association.

SOURCES: Juan Pablo Frias, MD, medical director of the Los Angeles National Research Institute; John B. Buse, MD, Ph.D., head of the endocrinology division, Verne S. Caviness Distinguished Professor, Director, Diabetes Center, Director NC University of North Carolina, North Carolina, Director of Chapel Hill University; Deena Adimoolam, MD, endocrinologist, New York City and spokesperson, Endocrine Society; Annual virtual meeting of the Endocrine Society, March 20-23, 2021

Source link


Leave a Reply

Your email address will not be published. Required fields are marked *